A comprehensive view of pfizer inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer and Valneva to start late-stage clinical study of experimental VLA15 Lyme disease vaccination with 6,000 participants in US, northern Europe; in June, Pfizer invested US$92.3M in Valneva to support Lyme disease partnership

Pfizer acquires Global Blood Therapeutics for US$5.4B, with deal closing expected in Q4 2022; deal includes Global Blood Therapeutics’ oral sickle cell drug Oxbryta, which had Q1 sales of US$55M

Compliance firm Model N launches Transparency Talks aimed at pharmaceutical, biotech companies to discuss state drug pricing laws, regulations and best practices; talks feature leaders from Model N, Pfizer, Global Pricing Innovations

US HHS warns that purchase of up to 171 million doses of bivalent COVID-19 booster doses from Pfizer, Moderna is not enough to treat entire US population; option to buy additional 600 million doses will need additional funding from Congress

FDA approves emergency use authorization for Moderna and Pfizer-BioNTech COVID-19 vaccines for children as young as six months old; Moderna vaccine administered in two doses, Pfizer vaccine administered in three doses

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count